<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82976">
  <stage>Registered</stage>
  <submitdate>12/07/2008</submitdate>
  <approvaldate>31/07/2008</approvaldate>
  <actrnumber>ACTRN12608000373370</actrnumber>
  <trial_identification>
    <studytitle>A Pilot Study With the IDEAL TM Bioabsorbable Coronary Stent Platform Eluting Sirolimus (WHISPER)</studytitle>
    <scientifictitle>A Pilot Study Evaluating the Safety and Performance of the IDEAL TM Bioabsorbable Coronary Stent Platform Eluting Sirolimus for the Treatment of Patients with Coronary Artery Disease</scientifictitle>
    <utrn />
    <trialacronym>WHISPER</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The IDEAL TM Coronary Stent is a biodegradable, drug eluting coronary stent that is implanted through a small incision in the groin area using standard interventional technique (as is done for the placement of any coronary stent) for minimally invasive cardiovascular procedures.  Patients who present with a lesion amenable to stent placement and meet the protocol's eligibility criteria may be enrolled and undergo placement of one IDEAL stent.</interventions>
    <comparator>N/A</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is ischemia-driven Target Lesion Failure.  Target Lesion Failure is when the lesion requires repeat treatment or results in a myocardial infarction (MI).  Ischemia driven means that the repeat intervention is the result of known ischemia.  This data will be extracted from the master study database using a statistical analysis software (SAS) or similar and analyzed by a qualified statistician.</outcome>
      <timepoint>Target Lesion Failure to 6 months post implant.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia-driven Major Adverse Cardiac Events (MACE) measured by
Ischemia-driven Target Vessel Failure (TVF)
ID-Target Lesion Revascularization (ID-TLR) and ID-Target Vessel Revascularization (ID-TVR)
Acute success (device and clinical procedure )
Stent thrombosis (Definite or probable per the Academic Research Consortium (ARC) definition )</outcome>
      <timepoint>This outcome will be assessed at 30 days, 6 months, 12 months and 24 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The patient has documented evidence of ischemic heart disease or a positive functional study.
2. The patient has a single de novo target lesion in a native coronary artery.
4. Target lesion stenosis is greater than 50% and less than 100%.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. The patient has a restenotic target lesion.
2. The patient has a lesion involving a bifurcation &gt; 2mm in diameter and ostial lesion &gt; 40% stenosis or side branch requiring dilatation.
3. Target vessel contains visible thrombus.
4. The patient has an inability to tolerate, adverse reaction, or contraindication to taking study medications or device materials.  
5. The target lesion is a total occlusion.
6.  Myocardial Infarction (MI) within 48 hours.
7. The patient has more than one lesion requiring treatment in the target vessel.
8. The patient has one or more non-target lesion requiring treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>13/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bioabsorbable Therapuetics, LTD</primarysponsorname>
    <primarysponsoraddress>Level 11 Petherick Tower, 38-42 Waring Taylor Street
The Terrace, Wellington</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bioabsorbable Therapuetics, LTD</fundingname>
      <fundingaddress>Level 11 Petherick Tower, 38-42 Waring Taylor Street
The Terrace, Wellington
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being performed to evaluate the safety and performance of the IDEAL Stent for the treatment of patients with cardiovascular disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IRB-ZNA-OCMW Antwerpen</ethicname>
      <ethicaddress>Commissie voor Medische Ethiek
ZNA Middleheim, Lindendreef 1, 2020, Antwerpen</ethicaddress>
      <ethicapprovaldate>9/01/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Belgium</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pat Rivelli</name>
      <address>Level 11 Petherick Tower, 38-42 Waring Taylor Street
The Terrace, Wellington</address>
      <phone>650-617-0740</phone>
      <fax />
      <email>www.bioabsorbabletx.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Pat Rivelli</name>
      <address>Level 11 Petherick Tower, 38-42 Waring Taylor Street
The Terrace, Wellington</address>
      <phone>650-617-0740</phone>
      <fax />
      <email>www.bioabsorbabletx.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>